| scholarly article | Q13442814 |
| P50 | author | Craig M. Crews | Q24006690 |
| Fazal Shirazi | Q59684501 | ||
| Ram K Singh | Q86730087 | ||
| Robert Z Orlowski | Q91428664 | ||
| P2093 | author name string | Jing Lu | |
| Hua Wang | |||
| R Eric Davis | |||
| Xiaohui Zhang | |||
| Zhiqiang Wang | |||
| Isere Kuiatse | |||
| Richard J Jones | |||
| Veerabhadran Baladandayuthapani | |||
| Yared Hailemichael | |||
| Heather Lin | |||
| Sheeba K Thomas | |||
| Kevin G Coleman | |||
| Bingzong Li | |||
| Huihan Wang | |||
| Zuzana Berkova | |||
| Yimin Qian | |||
| Hans C Lee | |||
| Kanak Raina | |||
| P2860 | cites work | Selective inhibition of BET bromodomains | Q24301009 |
| Identification of a primary target of thalidomide teratogenicity | Q24302178 | ||
| Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting | Q24308867 | ||
| mTOR signaling in growth control and disease | Q24634174 | ||
| BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models | Q27679878 | ||
| The PtdIns3-phosphatase MTMR3 interacts with mTORC1 and suppresses its activity | Q28117863 | ||
| BET bromodomain inhibition as a therapeutic strategy to target c-Myc | Q28247024 | ||
| Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery | Q28260105 | ||
| PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding | Q28302887 | ||
| Pim kinase-dependent inhibition of c-Myc degradation | Q28592035 | ||
| DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation | Q28830958 | ||
| Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study | Q33431391 | ||
| Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. | Q34020965 | ||
| Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation | Q34083015 | ||
| Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin | Q34130459 | ||
| Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. | Q34210005 | ||
| Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients | Q34410261 | ||
| Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. | Q34479551 | ||
| The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma | Q34500544 | ||
| Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide | Q34719436 | ||
| Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma | Q35097105 | ||
| Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. | Q35236076 | ||
| mLST8 Promotes mTOR-Mediated Tumor Progression | Q35612865 | ||
| SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway | Q35761691 | ||
| Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. | Q36333522 | ||
| The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma | Q36444233 | ||
| Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. | Q36638686 | ||
| Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1 | Q36717999 | ||
| Synergistic action of master transcription factors controls epithelial-to-mesenchymal transition | Q36775585 | ||
| A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma | Q36799900 | ||
| Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma | Q36868120 | ||
| Taking on challenging targets: making MYC druggable | Q36967922 | ||
| Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers | Q37031640 | ||
| Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy | Q37031949 | ||
| Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group | Q37037265 | ||
| PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer | Q37065079 | ||
| Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma | Q37148117 | ||
| Characterization of MYC translocations in multiple myeloma cell lines | Q37331601 | ||
| NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers | Q37638021 | ||
| Targeting PI3K/mTOR Signaling in Cancer | Q37725655 | ||
| Role of PRAS40 in Akt and mTOR signaling in health and disease. | Q37987085 | ||
| Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation | Q38266874 | ||
| Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: chemical modulation of chromatin structure | Q38276267 | ||
| Impact of MYC on malignant behavior | Q38361597 | ||
| Cereblon binding molecules in multiple myeloma | Q38406398 | ||
| RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma. | Q38709232 | ||
| Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs. | Q38909210 | ||
| Overexpression of c-myc is associated with adverse clinical features and worse overall survival in multiple myeloma | Q39723214 | ||
| Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells | Q40220260 | ||
| c-MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF-BB. | Q40299012 | ||
| Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation | Q40558374 | ||
| GATA-2/estrogen receptor chimera regulates cytokine-dependent growth of hematopoietic cells through accumulation of p21(WAF1) and p27(Kip1) proteins | Q40695236 | ||
| Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy | Q41964351 | ||
| Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. | Q44598583 | ||
| Proteasome inhibitors in cancer therapy. | Q53752929 | ||
| Proteasome inhibition leads to dephosphorylation and downregulation of protein expression of members of the Akt/mTOR pathway in MCL. | Q54513603 | ||
| The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization | Q73516520 | ||
| Drug resistance in multiple myeloma | Q73964906 | ||
| P433 | issue | 10 | |
| P304 | page(s) | 2224-2239 | |
| P577 | publication date | 2018-03-27 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma | |
| P478 | volume | 32 |
| Q93018654 | Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer |
| Q90287849 | BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction |
| Q61809000 | Bivalent Ligands for Protein Degradation in Drug Discovery |
| Q89810816 | Characterization of cereblon-dependent targeted protein degrader by visualizing the spatiotemporal ternary complex formation in cells |
| Q90154843 | Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites |
| Q96610114 | Discovering and validating cancer genetic dependencies: approaches and pitfalls |
| Q90481540 | Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies |
| Q99565924 | Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets |
| Q58738119 | Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs |
| Q64054218 | The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors |
Search more.